Abstract Library

#2141 Potential Role of SST5TMD4-Derived Peptides in the Malignancy of Neuroendocrine Tumors and Other Endocrine-Related Cancer Cells

Introduction: Extracellular fragments derived from membrane receptors can play relevant functional roles in certain tumoral pathologies and could provide novel diagnostic or therapeutic tools. We have identified a novel truncated somatostatin receptor type 5 variant, sst5TMD4, which is overexpressed and functionally active in different endocrine-related cancers, including neuroendocrine tumors (NETs). Interestingly, sst5TMD4 has 4 transmembrane domains and its C-terminal tail is consequently exposed towards the extracellular matrix, and could, therefore, be the substrate for proteolytic enzymes.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Pedraza-Arévalo S, Del Río-Moreno M, Alors-Pérez E, Castaño J, Luque R,

Keywords: sst5TMD4, derived peptides, malignancy, endocrine-related cancer,

#1906 High Prevalence of the c.1546delC Germline Mutation in MEN1 Pancreatic Neuroendocrine Tumors

Introduction: Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disease predisposing to pancreatic neuroendocrine neoplasms (NENs). Even though its genetics is relatively well known, specific phenotype-genotype correlations remain unproven at present. The Region of Murcia in southeast Spain is one of the areas with the highest incidence of MEN1

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Marín Zafra G

Authors: Marín Zafra G, Carmona-Bayonas A, Segura Luque P, Rodríguez González J, Tebar Massó J,

Keywords: MEN1 genetics,

#1772 Expression of Truncated Functional Subtype 5 Somatostatin Receptor Variant (sst5TMD4) in GEP-NETs and Association with Relevant Pathways Involved in NET Tumorigenesis

Introduction: Sst5TMD4, which is derived from a non-canonical splicing process of sst5 receptor, is overexpressed in several endocrine tumors and associated with a worse prognosis.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Diaz Perez A, Martínez-Fuentes A, García-Carbonero R, Luque R, Jimenez-Fonseca P,

Keywords: somatostatin receptor, neuroendocrine tumors,

#929 Prognostic Role of Smoking in Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)

Introduction: Large retrospective series identified several prognostic factors for GEP-NET such as sex, race, age, primary localization, stage or tumor grade. Several studies suggested a prognostic role of smoking in many cancer types. However, no data has been reported in GEP-NET.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Pons F, Mar I, Gallego , Luque A, González ,

Keywords: smoking, prognostic, gastroenteropancreatic, neuroendocrine tumor,

#422 The Somatostatin Analogue Octreotide Inhibits Growth of Neuroendocrine Tumor Cells by Triggering Janus Faced Proteins

Introduction: Octreotide is a somatostatin analogue, which improves the management of neuroendocrine tumor (NET) patients. Octreotide acts through somatostatin receptors (SSTRs). However, the molecular mechanisms leading to successful therapy or curative effects are largely unknown, particularly when SSTRs levels are low or absent.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Li S, Martijn C, Cui T, Essaghir A, Luque R,

Keywords: CNDT2.5, Octreotide, neuroendocrine cell growth/differentiation,